This medication is relevant for the relief of pain, fever, and chest congestion. It is commonly used for managing symptom clusters such as headache, toothache, muscle discomfort, body aches, and fever associated with seasonal illnesses. The combination may assist with easing associated muscular tension and stiffness, contributing to easing the overall symptom load during symptomatic periods.

In the context of colds or flu, the medication is also relevant for easing symptoms that create noticeable functional strain in the chest area, and helps address symptom clusters related to heightened physiological activity.

Quick Fact: Supports Management of Musculoskeletal Tension

Regulatory References

1. Health Canada Labelling Standard for Cold and Flu

Who Can and Cannot Use Ataralgin? (Population Eligibility)

Official regulatory information strictly defines the populations eligible to use this medicine, a fixed-dose combination of Acetaminophen, Caffeine, and Guaifenesin.

Contraindications and Prohibitions

Use is contraindicated and must be avoided in several specific populations:

• Patients with documented hypersensitivity or allergic reaction to Acetaminophen, Caffeine, Guaifenesin, or any other component in the product.
• Individuals with severe active liver disease or severe hepatocellular insufficiency.
• Patients with severe, uncontrolled hypertension or severe coronary artery disease.
• Individuals who are concurrently using any other medicine containing Acetaminophen due to the critical risk of severe liver damage.
• Patients who have used a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Restricted and Age-Based Eligibility

• Age Eligibility: Use is established for adults and adolescents generally 12 years of age and older. The use is not recommended in children under the specified minimum age threshold.
• Conditional Use: Patients with chronic alcoholism, mild-to-moderate liver disease, or certain pre-existing conditions like heart disease or hyperthyroidism require specific professional guidance before use.
• Pregnancy and Lactation: Use in pregnant and breastfeeding individuals is not unilaterally permitted and requires a health professional's consultation before administration.

Interactions with other medicines and products

Official regulatory information regarding Ataralgin interactions focuses on the combined effects of its components: paracetamol, propyphenazone, and caffeine. Interactions are primarily classified based on their potential to alter drug exposure or potentiate pharmacodynamic effects.

---

Pharmacokinetic and Toxicity Interactions

Mechanism/Classification	Interacting Substances (Examples)
Increased Toxin Formation	Enzyme inducers, such as Barbiturates, Phenytoin, or Carbamazepine
Altered Absorption Rate	Metoclopramide (increase), Cholestyramine (decrease)
Risk of Hepatotoxicity	Alcohol (consumption is strongly restricted)

---

Pharmacodynamic and Clinical Impact Interactions

Concomitant use with certain substances requires monitoring or avoidance due to additive clinical effects:

• Oral Anticoagulants (e.g., Warfarin): Regular, prolonged use of paracetamol can enhance the anticoagulant effect, requiring close monitoring of Prothrombin Time.
• Other Stimulants: Caffeine contributes to central nervous system (CNS) stimulation, and co-administration with other stimulants may increase adverse effects like agitation or elevated heart rate.
• Zidovudine: Co-administration with paracetamol may increase the risk of neutropenia, necessitating caution and monitoring.

Certain drug classes, such as pyrazolone derivatives, should generally be avoided due to potential cross-sensitivity and increased toxicity risk.

Ataralgin is a combination product whose pharmacodynamic action is exerted through the distinct mechanisms of its three components: Paracetamol, Caffeine, and Guaifenesin.

Central Inhibition of Prostaglandin Synthesis

Paracetamol's primary action involves the inhibition of cyclooxygenase (COX) enzymes, particularly within the central nervous system (CNS). This effect reduces the synthesis of prostaglandins, which are key lipid mediators of pro-nociceptive and pyrogenic signaling. This modification leads to a predictable physiological adjustment characterized by a reduction in central pro-nociceptive and pyrogenic signal transmission.

---

Augmentation of Central Stimulatory Signaling

Caffeine functions as a non-selective antagonist at adenosine receptors in the CNS. By blocking the binding of inhibitory adenosine, this action modifies neural signaling pathways involved in fatigue and alertness, resulting in modulation of central nervous system arousal and vigilance.

---

Enhancement of Respiratory Tract Secretion

Guaifenesin acts as a secretagogue, increasing the volume of respiratory tract fluid, potentially through a vagal reflex mechanism. This alters the physiochemistry of mucus by reducing its viscoelasticity and enhancing sol-layer hydration, which modifies the systemic physiological outcomes related to mucus mobility.

How to Use Ataralgin

The administration of Ataralgin, a fixed-dose combination product containing acetaminophen, caffeine, and guaifenesin, is based on specific instructions. This product is formulated for oral use as a tablet. The use pattern is structured to manage the total intake of the three active ingredients, ensuring adherence to defined limits and intervals.

---

Dosing and Administration Parameters

Parameter	Guideline
Route of Administration	Oral route
Standard Single Dose	1 to 2 tablets
Maximum Total Daily Dose	6 tablets (within 24 hours)
Minimum Dosing Interval	At least 4 hours must elapse between doses
Age Restriction	Dosing applies to adults and adolescents 15 years of age and older. The medicine is not intended for use in children under 15 years.
Administration Timing	No specific requirement is noted regarding taking the tablet with or without food.

---

Procedural Framework for Administration

The usage protocol for Ataralgin is defined by its precise scheduling and quantity limits. Individuals 15 years and older are instructed to take a single dose of 1 or 2 tablets. This dose may be repeated, but a mandatory minimum interval of four hours must be observed before administering the next dose. Strict adherence to the maximum daily intake of six tablets is required to remain within the specified parameters. This administration pattern establishes a precise, time-interval-dependent approach to using the medicine.

Research Evidence / Overview of Studies

Clinical research has explored the effects of Ataralgin, a fixed-dose combination analgesic, across various common pain conditions. Studies have primarily focused on evaluating its use in addressing acute pain symptoms, such as headache and dental pain, and its general tolerability profile.

---

Focus Area 1: Efficacy in Acute Pain Syndromes

Research has explored whether Ataralgin is associated with changes in pain intensity over short treatment periods. A number of randomized controlled trials (RCTs) evaluated the percentage of participants reporting pain relief after single and repeated doses across different populations.

• Trials comparing the fixed combination to placebo or individual components are available, exploring the onset of effect and sustained relief over a few hours following administration.
• The combination of three active ingredients is intended to target pain via different pathways, and research has evaluated whether this multi-modal approach affects overall efficacy outcomes.

---

Focus Area 2: Tolerability and Pharmacokinetics

Research has assessed the general safety and tolerability of Ataralgin in short-term use, which is typical for acute analgesic medications. Studies document the frequency of participant-reported side effects and discontinuation rates.

• Pharmacokinetic studies examined the absorption, distribution, metabolism, and excretion of the individual components (paracetamol, propyphenazone, and caffeine) when taken together in the fixed formulation.
• Specifically, research has explored how caffeine affects the absorption rate of the other analgesic components, which may be a factor in the time to peak plasma concentration.

---

Focus Area 3: Comparison to Analgesic Classes

Studies have sometimes included comparisons between the Ataralgin combination and other common analgesic classes, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or paracetamol alone. These comparisons typically evaluate the clinical equivalence of the treatments against specific pain models, such as headache or post-operative dental pain, focusing on metrics like the Sum of Pain Intensity Differences (SPID).

Key Studies & References

1. Oral Analgesics for Acute Dental Pain (ADA-endorsed guidelines content)

Common questions about Ataralgin (FAQ)

Q: How long does it typically take for Ataralgin to start working?

According to official regulatory information, the active components in Ataralgin are reported to reach their maximum concentration in the blood within 30 to 60 minutes. This suggests the approximate time to the onset of the effect.

Q: How long can a person expect the effects of Ataralgin to last?

Official regulatory information indicates the therapeutic effect is generally sustained over a 4 to 6-hour period. The primary effect is intended to last for several hours.

Q: Does Ataralgin interact with common caffeine-containing beverages like coffee?

Since caffeine is an active ingredient in this medicine, official warnings advise considering the total intake of caffeine. Limiting the total intake is generally advised to avoid potential side effects such as nervousness, sleeplessness, and palpitations.

Q: What official documents contain the complete list of known risks for Ataralgin?

The comprehensive safety and risk information for Ataralgin is detailed in the official regulatory product information. These documents, such as the Summary of Product Characteristics (SmPC), document the known adverse effects, warnings, and contraindications.

Q: Can people who are sensitive to caffeine take Ataralgin?

Official guidance requires consultation with a healthcare professional for individuals with a known sensitivity to caffeine or those with pre-existing heart rhythm issues. The caffeine component in the medicine is a stimulant that may aggravate certain conditions.

Q: Is Ataralgin generally considered well-tolerated?

Regulatory data indicates that the active components are generally well-tolerated when the medicine is used as directed. Official information also includes a recommendation to report any adverse events, which can include common occurrences like nausea, dizziness, or tiredness.

Q: What specific type of pain receptors does Ataralgin's action involve?

Official pharmacological descriptions indicate that the medicine works primarily by inhibiting cyclooxygenase (COX) enzymes in the central nervous system. This action modifies the production of chemical compounds responsible for signaling pain and fever throughout the body.

Q: Why do some users report feeling sleepy after taking Ataralgin?

Official safety information from clinical trials lists general tiredness (fatigue) and dizziness as known, though typically low-frequency, side effects. General drowsiness or sleepiness is not specifically listed in the adverse events profile.

Q: Can Ataralgin be taken with common over-the-counter (OTC) supplements?

Regulatory safety guides address the use of this medicine alongside other substances. Official guidance requires consultation with a healthcare professional regarding the use of Ataralgin with vitamins, herbal remedies, or dietary supplements, as interactions are possible.

Q: Is Ataralgin suitable for use by older adults or seniors?

Official warnings indicate that due to the NSAID component (Propyphenazone), older individuals may face increased general risk factors. Official guidance therefore requires consultation with a healthcare professional before use in older adults.

Q: Is there any restriction on driving or operating machinery while using Ataralgin?

Official regulatory warnings advise caution regarding activities like driving or operating heavy machinery. This is because potential side effects such as dizziness or tiredness may affect alertness, and individuals experiencing impairment should not drive.

Q: Does Ataralgin carry any potential risk for physical dependence?

According to official documentation, Ataralgin contains only non-opioid analgesics. For this reason, the medicine is not classified as having a risk of physical dependence or addiction.

Q: Does Ataralgin interact with commonly prescribed antidepressant medications?

Official warnings state the medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). For other classes of antidepressant medications, individuals are required to discuss the use of Ataralgin with a prescribing professional due to potential interactions.

Q: Are there different strengths or formulations of Ataralgin available?

Ataralgin is formulated as a fixed-dose combination product. The specific strengths of its three active ingredients—Paracetamol, Propyphenazone, and Caffeine—are detailed on the official product label.

Q: Does Ataralgin interact with blood pressure medications?

An interaction is known with certain blood pressure medications (antihypertensives), as the caffeine and propyphenazone components can affect blood pressure regulation. Official guidance requires consultation with a healthcare professional before use.

Q: Can a person take Ataralgin if they have asthma or breathing difficulties?

As the medicine contains an NSAID component, official guidance requires consultation with a healthcare professional for patients with asthma or a history of sensitivity to aspirin or other NSAIDs.

Q: Are there any studies examining the long-term safety profile of Ataralgin?

Official regulatory information strictly indicates that this medicine is for short-term use and temporary relief. Professional medical guidance is needed to determine the appropriateness of use beyond the stated duration.

Q: Is there an established maximum duration for using Ataralgin?

Official warnings define duration limits for temporary relief. The medicine should not be taken for fever for more than three days or for pain for more than seven days; professional review is advised if these duration limits are exceeded.

Storage and Environmental Conditions

Official regulatory documents mandate that Ataralgin tablets must be stored at a temperature not exceeding 25 °C. To ensure product stability and integrity, the medicine requires specific protection conditions, including keeping it protected from light and moisture. For this reason, the tablets must remain stored in the original packaging.

Child-Safety and Disposal

A primary storage instruction requires that Ataralgin be kept out of the sight and reach of children.

When disposing of unused or expired medicine, regulatory instructions prohibit throwing the product into wastewater or household waste. The appropriate method for disposal is to return the unused medicine to a pharmacist, ensuring the product is discarded according to local pharmaceutical waste requirements to protect the environment.